Veliparib does not lock PARP-1 enzyme onto DNAas potently as otherinhibitors,24 and its more favorable hematotoxicityprofile makes it an attractive alternative for combination chemotherapies.This inhibitor received an FDA orphan drug designation for the treatmentof epithelial ovarian cancer in combination with DNA-damaging agentsas well as for advanced squamous non-small-cell lung cancer.25 This evidence concerns the gene PARP1 and ovarian carcinoma.